HIV can develop resistance to lenacapavir, but at a cost to the virus
Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game…
Unveiling the dual role of HIV integrase in viral replication
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most…
Breakthrough reveals how viruses efficiently pack genetic material
Researchers at San Diego State University and Michigan State University are shedding new light on how viruses meticulously…